EUVIMEDEUVIMED entdecken
Crossref

Rapid disease progression of myelodysplastic syndrome is reflected in transcriptomic and functional abnormalities of bone marrow mesenchymal stromal cells

Hein Than, Xiubo Fan, Alice M S Cheung, William Y K Hwang, Zhiyong Poon iD

Stem Cells · 2025

DOI: 10.1093/stmcls/sxae073 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stem Cells, 2025. Verfasst von Hein Than und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Singapore General Hospital, Singapore 169608. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Mesenchymal Stem Cells, Transcriptome, Bone Marrow Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bone marrow (BM) mesenchymal stromal cells (MSCs) are important regulators of hematopoietic stem and progenitor cells (HSPCs). When transformed into a dysplastic phenotype, MSCs contribute to hematopoietic diseases such as myelodysplastic syndromes (MDS), but it remains unclear if there are specific properties in MDS-MSCs that contribute to the disease course. To understand this, we investigated MDS-MSCs from fast (MDSfast) vs slow (MDSslow) progressing disease groups and discovered differences between these groups. MDSfast-MSCs secrete more inflammatory factors, support myeloid-skewed differentiation of HSPCs, and importantly, show poorer response to hypomethylation as a key differentiator in GSEA analysis. When exposed to long-term in vivo stimulation with primary MDSfast-MSCs-based scaffolds, healthy donor (HD) HSPCs show elevated NF-κB expression, similar to leukemic HSPCs in MDS. Those “MDSfast-MSCs-primed” HD-HSPCs continue to show enhanced engraftment rates in secondary MDS-MSC-based scaffolds, providing evidence for the microenvironmental selection pressures in MDS toward leukemic HSPCs. Together, our data point toward a degree of co-development between MSCs and HSPCs during the progression of MDS, where changes in MDS-MSCs take place mainly at the transcriptomic and functional levels. These unique differences in MDS-MSCs can be utilized to improve disease prognostication and implement targeted therapy for unmet clinical needs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesMesenchymal Stem CellsTranscriptomeBone Marrow CellsHumansDisease ProgressionCell DifferentiationAnimalsFemaleMaleHematopoietic Stem CellsMiddle Aged

Stichwörter der Autor:innen

bone marrow microenvironmentmesenchymal stromal cellsmyelodysplastic syndromes

Autor:innen und Institutionen

  • Department of Hematology, Singapore General Hospital, Singapore 169608.
  • Duke-NUS Medical School, National University of Singapore, Singapore 169857.
  • Department of Hematology, National Cancer Center, Singapore 168583.
  • Department of Clinical Translational Research, Singapore General Hospital, Singapore 169608.

ORCID-Profile: Zhiyong Poon

Zitieren

APA

Than, H., Fan, X., Cheung, A. M. S., Hwang, W. Y. K., & Poon, Z. (2025). Rapid disease progression of myelodysplastic syndrome is reflected in transcriptomic and functional abnormalities of bone marrow mesenchymal stromal cells. Stem Cells. https://doi.org/10.1093/stmcls/sxae073

Vancouver

Than H, Fan X, Cheung AMS, Hwang WYK, Poon Z. Rapid disease progression of myelodysplastic syndrome is reflected in transcriptomic and functional abnormalities of bone marrow mesenchymal stromal cells. Stem Cells. 2025. doi:10.1093/stmcls/sxae073

BibTeX
@article{Than2025,
  author = {Than, Hein and Fan, Xiubo and Cheung, Alice M S and Hwang, William Y K and Poon, Zhiyong},
  title = {Rapid disease progression of myelodysplastic syndrome is reflected in transcriptomic and functional abnormalities of bone marrow mesenchymal stromal cells},
  journal = {Stem Cells},
  year = {2025},
  doi = {10.1093/stmcls/sxae073}
}
Kostenlos starten →